Key facts
- This page summarizes Michael C. Donegan's Form 4 filing for TherapeuticsMD, Inc. (TXMD).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Apr 2023, 19:17.
Michael C. Donegan - 12 Apr 2023 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)
- Reporting relationship
- Prin. Fin. and Acctg. Officer
- Issuer ticker
- TXMD
- Reported as of
- 12 Apr 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Apr 2023, 19:17:22 UTC
- Prior SEC filing
- 23 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael C. Donegan
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael C. Donegan filed Form 4 for TherapeuticsMD, Inc. (TXMD) on 14 Apr 2023.
Change
- Previous filing in this sequence was filed on 23 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TXMD
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +50,000
- Change %
- +422%
- Price
- $0.000000
- Shares after
- 61,853
- Date
- 12 Apr 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TXMD
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -50,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 12 Apr 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $0.000000
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On April 12, 2023, the reporting person received 50,000 shares of issuer common stock in settlement of restricted stock units (RSUs).
Footnote F2
Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on March 31, 2023.